Literature DB >> 15291726

Factors influencing Stroop performance in schizophrenia.

Deanna M Barch1, Cameron S Carter, Jonathan D Cohen.   

Abstract

Recent studies suggest that individuals with schizophrenia show enhanced facilitation but similar interference in reaction times (RTs), compared with control participants, combined with increased error interference. This study examined the relationship between errors and RTs on the Stroop task among individuals with schizophrenia. The authors examined performance on a speeded Stroop task, designed to increase errors, in 29 individuals with schizophrenia and 29 nonpatient control participants. The authors also analyzed color-naming and word-reading estimates from process dissociation analyses. The findings suggest that a lack of increased RT interference among patients (compared with control participants) is not solely due to the increased number of errors they produce in the incongruent condition but is also influenced by a greater impact of the word even in the neutral condition.

Entities:  

Mesh:

Year:  2004        PMID: 15291726     DOI: 10.1037/0894-4105.18.3.477

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  15 in total

1.  Probabilistic reinforcement learning in adults with autism spectrum disorders.

Authors:  Marjorie Solomon; Anne C Smith; Michael J Frank; Stanford Ly; Cameron S Carter
Journal:  Autism Res       Date:  2011-03-18       Impact factor: 5.216

Review 2.  CNTRICS final task selection: executive control.

Authors:  Deanna M Barch; Todd S Braver; Cameron S Carter; Russell A Poldrack; Trevor W Robbins
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

3.  Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns.

Authors:  César González-Blanch; Mario Alvarez-Jiménez; José Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; José Luis Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-20       Impact factor: 5.270

4.  Attention Problems as a Mediator of the Relation between Executive Function and Social Problems in a Child and Adolescent Outpatient Sample.

Authors:  Dane C Hilton; Matthew A Jarrett; Kristina L McDonald; Thomas H Ollendick
Journal:  J Abnorm Child Psychol       Date:  2017-05

5.  Stroop test performance in impulsive and non impulsive patients with Parkinson's disease.

Authors:  Atbin Djamshidian; Sean S O'Sullivan; Andrew Lees; Bruno B Averbeck
Journal:  Parkinsonism Relat Disord       Date:  2011-01-17       Impact factor: 4.891

6.  Influence of empathetic pain processing on cognition in schizophrenia.

Authors:  Kesong Hu; Marijn Lijffijt; Theodore P Beauchaine; Zhiwei Fan; Hui Shi; Shuchang He
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-12-05       Impact factor: 5.270

7.  Color Stroop and negative priming in schizophrenia: an fMRI study.

Authors:  Lida Ungar; Paul G Nestor; Margaret A Niznikiewicz; Cynthia G Wible; Marek Kubicki
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

8.  Neural correlates of impaired cognitive control over working memory in schizophrenia.

Authors:  Teal S Eich; Derek Evan Nee; Catherine Insel; Chara Malapani; Edward E Smith
Journal:  Biol Psychiatry       Date:  2013-10-10       Impact factor: 13.382

9.  Schizophrenia patients show task switching deficits consistent with N-methyl-d-aspartate system dysfunction but not global executive deficits: implications for pathophysiology of executive dysfunction in schizophrenia.

Authors:  Glenn R Wylie; E A Clark; P D Butler; D C Javitt
Journal:  Schizophr Bull       Date:  2008-10-03       Impact factor: 9.306

10.  Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test.

Authors:  Carolin Opgen-Rhein; Andres H Neuhaus; Carsten Urbanek; Eric Hahn; Thomas Sander; Michael Dettling
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.